Phase II study of MS 275, a histone deacetylase inhibitor, comparing 2 dosage schedules in patients with metastatic melanoma
Phase of Trial: Phase II
Latest Information Update: 15 Dec 2015
At a glance
- Drugs Entinostat (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bayer
- 22 Jan 2009 Actual end date and trial identifier (91410) added from ClinicalTrials.gov.
- 01 Aug 2008 Results published in Melanoma Research.
- 04 Dec 2006 The expected completion date for this trial is now 1 Nov 2006.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History